Cargando…

Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter

In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atria...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Vincent K., Kavanagh, Katherine M., Raj, Satish R., Pollak, P. Timothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402954/
https://www.ncbi.nlm.nih.gov/pubmed/36035739
http://dx.doi.org/10.1016/j.cjco.2022.04.006
_version_ 1784773259986731008
author Le, Vincent K.
Kavanagh, Katherine M.
Raj, Satish R.
Pollak, P. Timothy
author_facet Le, Vincent K.
Kavanagh, Katherine M.
Raj, Satish R.
Pollak, P. Timothy
author_sort Le, Vincent K.
collection PubMed
description In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atrial flutter was successfully cardioverted using an atypically large, 8000-mg oral amiodarone dose. The only adverse effect was transient sinus arrest, which did not require intervention, only 24 hours of inpatient monitoring. Amiodarone’s unique pharmacokinetics, including its long elimination half-life and its extensive distribution into a large volume of adipose tissue, make high-dose oral amiodarone boluses a reasonable strategy for cardioversion of atrial arrhythmias.
format Online
Article
Text
id pubmed-9402954
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-94029542022-08-26 Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter Le, Vincent K. Kavanagh, Katherine M. Raj, Satish R. Pollak, P. Timothy CJC Open Case Report In atrial arrhythmias, amiodarone is usually given either intravenously for acute management, requiring in-hospital monitoring, or orally for chronic control, as doses given 60 times per half-life, requiring weeks to reach full effect. A high-risk, 245-kg male with heart failure exacerbated by atrial flutter was successfully cardioverted using an atypically large, 8000-mg oral amiodarone dose. The only adverse effect was transient sinus arrest, which did not require intervention, only 24 hours of inpatient monitoring. Amiodarone’s unique pharmacokinetics, including its long elimination half-life and its extensive distribution into a large volume of adipose tissue, make high-dose oral amiodarone boluses a reasonable strategy for cardioversion of atrial arrhythmias. Elsevier 2022-04-28 /pmc/articles/PMC9402954/ /pubmed/36035739 http://dx.doi.org/10.1016/j.cjco.2022.04.006 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Le, Vincent K.
Kavanagh, Katherine M.
Raj, Satish R.
Pollak, P. Timothy
Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title_full Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title_fullStr Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title_full_unstemmed Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title_short Tolerance of High-Dose Oral Amiodarone for Cardioversion of Atrial Flutter
title_sort tolerance of high-dose oral amiodarone for cardioversion of atrial flutter
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402954/
https://www.ncbi.nlm.nih.gov/pubmed/36035739
http://dx.doi.org/10.1016/j.cjco.2022.04.006
work_keys_str_mv AT levincentk toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter
AT kavanaghkatherinem toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter
AT rajsatishr toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter
AT pollakptimothy toleranceofhighdoseoralamiodaroneforcardioversionofatrialflutter